Lundbeck posts a 24% increase in turnover for 2002  

Danish pharmaceutical company Lundbeck's 2002 turnover was DKK 9.488 billion, 24% up on the 2001 performance

Danish pharmaceutical company Lundbeck has published its annual accounts for 2002 showing a turnover of DKK 9.488 billion (USD 1.4 billion), a 24% increase compared with DKK 7.656 billion (USD 1.1 billion) in 2001. Pre-tax profit was DKK 2.075 billion (USD 307 million) which is 9% higher than last year, and the result after tax was DKK 1.269 billion (USD 187 million), 3% lower compared with 2001. According to the MD of Lundbeck, Erik Sprunk-Jansen, last year’s turnover was the largest in Lundbeck’s entire history despite the company having to face extremely tough competition.


There has been a small shift in the turnover of Lundbeck’s antidepressants from Cipramil (Celexa in US) to Cipralex (Lexapro in US). In 2002 Cipramil accounted for 54% of the turnover, compared with 59% in 2001. For Cipralex there was a small increase in its share of the turnover from 22% in 2001 to 25% in 2002. Lundbeck expects total turnover for 2003 to increase by 10% and operating profit to increase by 12%. The news is published on

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×